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identify potential new collaborators.2 Neverthe-
less, under the terms of approval of our retro-
spective study by the institutional review board, 
we are not permitted to release patient-level data. 
Our retrospective study includes not only patients 
in different clinical trials but also patients who 
received “standard of care” treatment that was 
not determined by a specific clinical protocol. 
Different consents apply to the different popula-
tions included in the analysis; therefore, in order 
to perform our retrospective study, we applied 
for and received specific approval from the insti-
tutional review board under internal protocol 
2281 of the Fred Hutchinson Cancer Research 
Center.
Furthermore, Hourigan and colleagues re-
quest disclosure of patient-level data pertaining 
to a large number of individual patient–related 
factors, some of which were not collected at the 
time of the chart review or included in the 
analysis. Although we agree that some of these 
factors might be worth examining, to collect, 
analyze, and release such information would 
require time and another institutional review 
board application.
In response to the other questions by Hourigan 
et al., bone marrow biopsies with cytogenetic 
analysis were performed before transplantation 
in all the patients with myelodysplasia. In our 
system, we do not have a way of determining 
how many patients are considered for transplan-
tation but do not undergo transplantation. The 
study by Walter et al. included transplants from 
both related and unrelated donors, and a total of 
152 patients in that study were also involved in 
our study. With the goal of sharing data among 
various institutions in the future, we are willing 
to submit a new institutional review board ap-
plication and collaborate with Hourigan and 
colleagues or others.
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The Nature of the P Value
To the Editor: Pocock and Stone (Sept. 8 issue) 
provide an excellent primer on evaluations of 
clinical trials and their applications to practice.1 
However, early on in their article they make a 
common but erroneous statement regarding the 
nature of the P value: “A P value of 0.05 carries a 
5% risk of a false positive result.” This miscon-
ception is found throughout statistical and med-
ical literature and was recently addressed in the 
following statement, published earlier this year 
by the American Statistical Association: “P-values 
do not measure the probability that the studied 
hypothesis is true, or the probability that the 
data were produced by random chance alone.”2 A 
P value is an expression of the probability of get-
ting results at least as extreme as what was ob-
served, under the assumption that the null hy-
pothesis is true.2,3 The P value as it was originally 
intended was simply meant to serve as a guide 
for evaluating whether an experiment was worth 
repeating.
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The authors reply: We appreciate Hu’s com-
ments on the meaning of P values. Of course, we 
endorse the statement from the American Statis-
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tical Association, which is compatible with the 
view of the original creators of the P value — 
R.A. Fisher and others — more than a century 
ago. (See Pocock et al.1 for a historical account 
that addresses some common misperceptions 
about P values.)
We disagree with Hu’s claim that our state-
ment — “A P value of 0.05 carries a 5% risk of a 
false positive result” when “there is no true dif-
ference between treatments” — is erroneous. 
According to the null hypothesis, P<0.05 will 
occur 5% of the time.
We also respectfully disagree with Hu’s last 
sentence, in which he states that “The P value as 
it was originally intended was simply meant to 
serve as a guide for evaluating whether an ex-
periment was worth repeating.” Fisher, in his 
seminal text, clearly described the P value as a 
tool to be used to determine the strength of 
evidence contradicting the null hypothesis, rec-
ognizing that the smaller the P value, the lower 
the likelihood of a false positive result.2
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TP53 and Histone H3.3 Mutations in Triple-Negative Lower-
Grade Gliomas
To the Editor: The genomic landscape of lower-
grade gliomas has recently been investigated in 
“multi-omic” analyses that have revealed mo-
lecular subgroups with prognostic relevance.1 In 
particular, robust biomarkers, including 1p/19q 
codeletion (deletion of chromosome arms 1p and 
19q), IDH mutation, and TERT promoter muta-
tion, have been used to classify international 
cohorts of gliomas into five principal molecular 
groups with clinical relevance.2 In the 2016 
World Health Organization (WHO) classification 
of central nervous system tumors,3 IDH and 
1p/19q are used as biomarkers to classify gliomas.
We evaluated tumor samples obtained from 
459 adults (mean age, 44 years; median age, 43 
years; range, 18 to 79) with grade II or III diffuse 
gliomas defined according to the molecular 
scheme (1p/19q codeletion and IDH and TERT 
mutations) described by Eckel-Passow et al.2 A 
total of 30.3% of these gliomas were triple-pos-
itive, 9.2% had IDH–TERT co-mutations, 28.1% 
had IDH mutations only, 17.4% were triple-nega-
tive, 5.9% had TERT mutations only, and 9.1% 
had other genetic combinations. The principal 
molecular subgroups had prognostic significance 
across the cohort; this significance was indepen-
dent of the patient’s age and the histologic type 
and grade of the tumor (see Fig. S1A and Table 
S1 in the Supplementary Appendix, available with 
the full text of this letter at NEJM.org).
The frequency of triple-negative gliomas was 
higher in our Chinese cohort than in the cohort 
described by Eckel-Passow et al. (17.4% vs. 7.0%).2 
We further examined this molecular subgroup 
for substratification of prognostic value. The sub-
stratification of clinical risk on the basis of the 
histologic grade of triple-negative gliomas was 
more robust than predictions of risk on the basis 
of histologic type (P<0.001) (see Fig. S1B in the 
Supplementary Appendix).
TP53 was sequenced in 21 triple-negative glio-
mas for which there was sufficient tissue for 
analysis; survival data were available for 20 pa-
tients (Fig. 1B). A significant proportion of pa-
tients (43%) had gliomas with TP53 mutations; 
these patients had shorter overall survival than 
those with wild-type TP53 (P = 0.03) (Fig. 1A).
H3.3-K27M, another biomarker used to cate-
gorize gliomas in the WHO 2016 classification,3 
was present in 19% of the triple-negative glio-
mas and was detected in the patients with re-
duced survival (P = 0.02) (Fig. 1A). Notably, all 
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